Loteprednol Ophthalmic Drug Interactions
- Alrex
- Eysuvis
- Inveltys
- Lotemax
- Lotemax SM
- Loteprednol Etabonate
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
About Loteprednol Ophthalmic
Ophthalmic loteprednol products are used to treat different eye conditions: Loteprednol (Inveltys, Lotemax, Lotemax SM) is used to treat swelling and pain after cataract surgery (procedure to treat clouding of the lens in the eye). Loteprednol (Alrex) is used to reduce eye redness, itching, and swelling caused by seasonal allergies.
Read the full Loteprednol Ophthalmic drug information pageQuick links
The Bottom Line on Loteprednol Ophthalmic
Desmopressin is the pairing to know about with loteprednol eye drops, which calm swelling, redness and itching in the eye. That combination is rated contraindicated because it can drop sodium in the blood to a severe degree. Aspirin and carbamazepine are also rated major. Aspirin can lead to too much salicylate once a corticosteroid is withdrawn, and carbamazepine can leave the corticosteroid working less well. Most of its interactions are serious, so filling every prescription at one pharmacy lets each new one be checked against it.
From the HelloPharmacist Editorial Team Written with AI from this page's interaction records · How we build these pages · How we use AI · Our editorial policy
Check Loteprednol Ophthalmic Against Another Drug or Supplement
Type a drug, a brand name or a supplement. We check it against every documented loteprednol ophthalmic interaction, supplements and herbs included.
What Could Happen When Loteprednol Ophthalmic Interacts
What the 29 documented loteprednol ophthalmic interaction records say could happen, grouped by the problem each one names. Tap a bar to see those drugs.
This chart covers drug interactions only. Interactions with supplements and herbs are studied far less, so they are not counted here; they have their own pages on this site. One interaction can name more than one problem, so the numbers add up to more than 29.
Loteprednol Ophthalmic Interactions by Severity
Contraindicated
- Loteprednol Ophthalmic and Desmopressin Explained Brand names: Ddavp, Stimate, Noctiva Increased risk of severe hyponatremia Details
- Loteprednol Ophthalmic and Mifepristone Explained Brand names: Korlym, Mifeprex An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details
Major
- Loteprednol Ophthalmic and Aspirin Explained Brand names: Entercote, Zorprin, Valomag An increased risk of salicylism subsequent to withdrawal of corticosteroids Details
- Loteprednol Ophthalmic and Bemiparin Explained Increased risk of bleeding Details
- Loteprednol Ophthalmic and Carbamazepine Explained Brand names: Carbatrol, Epitol, Equetro Reduced corticosteroids exposure and reduced efficacy of corticosteroids Details
- Loteprednol Ophthalmic and Cosyntropin Explained False elevations of plasma cortisol levels Details
- Loteprednol Ophthalmic and Ethinyl Estradiol Explained Increased corticosteroid exposure Details
- Loteprednol Ophthalmic and Fosphenytoin Explained Brand name: Cerebyx Reduced corticosteroid exposure Details
- Loteprednol Ophthalmic and Insulin Aspart, Recombinant Explained Brand names: Fiasp, Kirsty, Merilog Reduced blood glucose lowering effect of insulin Details
- Loteprednol Ophthalmic and Insulin Glargine, Recombinant Explained Brand names: Basaglar, Lantus, Rezvoglar Reduced blood glucose lowering effect of insulin Details
- Loteprednol Ophthalmic and Insulin Icodec-abae Explained Brand name: Awiqli Reduced efficacy of insulin icodec-abae Details
- Loteprednol Ophthalmic and Lutetium Lu 177 Dotatate Explained Decreased lutetium Lu 177 dotatate efficacy Details
- Loteprednol Ophthalmic and Macimorelin Explained Brand name: Macrilen False-positive or false-negative adult growth hormone deficiency diagnosis Details
- Loteprednol Ophthalmic and Nadroparin Explained Increased risk of bleeding Details
- Loteprednol Ophthalmic and Phenytoin Explained Brand names: Dilantin, Phenytek, Phenytoin Infatabs Reduced corticosteroid exposure Details
- Loteprednol Ophthalmic and Rabies Vaccine Explained Brand names: Imovax, RabAvert An inadequate immunological response to the vaccine, an increased risk of altered immunocompetence and reduced immune response to... Details
- Loteprednol Ophthalmic and Relacorilant Explained Brand name: Lifyorli Reduced relacorilant exposure and reduced efficacy of relacorilant, reduced glucocorticoids exposure and reduced efficacy of gluco... Details
- Loteprednol Ophthalmic and Sargramostim Explained Brand name: Leukine Increased myeloproliferative effects of sargramostim Details
- Loteprednol Ophthalmic and Somatrogon-ghla Explained Reduced serum cortisol exposure, an increased risk of central (secondary) hypoadrenalism and attenuated growth-promoting effects o... Details
- Loteprednol Ophthalmic and Upadacitinib Explained Brand name: Rinvoq Increased risk of gastrointestinal perforations Details
Look Up Another Drug
Still Have Questions About Loteprednol Ophthalmic?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
The References Behind Loteprednol Ophthalmic’s Interactions
The 90 sources our loteprednol ophthalmic interaction records cite: clinical studies, case reports and FDA prescribing information. Each pair's page lists the ones it rests on, numbered in its text, and a source link is one we checked against PubMed or Crossref. How we check them →
- Friedlaender MH & Howes J: A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997; 123:455-464. DOI
- Bartlett JD, Howes JF, Ghormley NR, et al: Safety and efficacy of loteprednol etabonate for treatment of papillae in contact les-associated giant papillary conjunctivitis. Curr Eye Res 1993; 12:313-321.
- Product Information: INVELTYS(TM) ophthalmic suspension, loteprednol etabonate ophthalmic suspension. Kala Pharmaceuticals Inc (per FDA), Waltham, MA, 2018. DailyMed
- Product Information: LOTEMAX(R) ophthalmic gel, loteprednol etabonate 0.5% ophthalmic gel. Bausch & Lomb Incorporated (per FDA), Tampa, FL, 2012. DailyMed
- Product Information: Lotemax(TM), loteprednol etabonate 0.5% ophthalmic suspension. Bausch & Lomb Pharmaceuticals, Inc, Tampa, FL, 1998. DailyMed
- Product Information: LOTEMAX(R) SM ophthalmic gel, loteprednol etabonate 0.38% ophthalmic gel. Bausch + Lomb (per manufacturer), Bridgewater, NJ, 2019. DailyMed
- Product Information: Lotemax(R) ophthalmic ointment, loteprednol etabonate 0.5% ophthalmic ointment. Bausch & Lomb Incorporated (per FDA), Tampa, FL, 2011. DailyMed
- Product Information: LOTEMAX(R) ophthalmic gel, loteprednol etabonate 0.5% ophthalmic gel. Bausch + Lomb (per DailyMed), Bridgewater, NJ, 2018. DailyMed
- Fong R, Silverstein BE, Peace JH, et al: Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. J Cataract Refract Surg 2018; 44(10):1220-1229. PubMed
- Rajpal RK, Fong R, & Comstock TL: Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv Ther 2013; 30(10):907-923. DOI